Novartis Ag (NVS) Long-Term Deferred Tax (2009 - 2026)
Novartis Ag (NVS) posted Long-Term Deferred Tax of $5.3 billion for Q2 2026, up 779.5% sequentially from $600.0 million in Q1 2026, and up 1.44% YoY from $5.2 billion in Q2 2025.
Novartis Ag (NVS) Long-Term Deferred Tax (2009 - 2026) Analysis & Trends
Novartis Ag has reported Long-Term Deferred Tax for 18 years, with the latest figure at $5.3 billion in Q2 2026.
- Quarterly Long-Term Deferred Tax rose 1.44% year-over-year to $5.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.3 billion (up 1.44% YoY) and the FY2025 annual result came in at $5.4 billion, up 1069.46% from the prior year.
- Long-Term Deferred Tax grew to $5.3 billion in Q2 2026 per NVS's latest filing, from $600.0 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $5.4 billion in Q4 2025 and troughed at $34.0 million in Q4 2023.
- A 5-year average of $2.2 billion and a median of $630.5 million in 2023 frame the typical range for Long-Term Deferred Tax.
- The widest YoY moves for Long-Term Deferred Tax: up 7528.3% in 2023, down 99.09% in 2023.
- Over 5 years, Long-Term Deferred Tax stood at $3.7 billion in 2022, then sank by 99.09% to $34.0 million in 2023, then jumped by 1267.65% to $465.0 million in 2024, then surged by 1069.46% to $5.4 billion in 2025, then declined by 2.96% to $5.3 billion in 2026.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $5.3 billion, $600.0 million, and $5.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.28 Bn |
| Mar 31, 2026 | 600.00 Mn |
| Dec 31, 2025 | 5.44 Bn |
| Jun 30, 2025 | 5.20 Bn |
| Dec 31, 2024 | 465.00 Mn |
| Sep 30, 2024 | 307.00 Mn |
| Jun 30, 2024 | 4.40 Bn |
| Dec 31, 2023 | 34.00 Mn |
| Sep 30, 2023 | 661.00 Mn |
| Jun 30, 2023 | 4.04 Bn |
| Dec 31, 2022 | 3.74 Bn |
| Sep 30, 2022 | 53.00 Mn |
| Jun 30, 2022 | 53.00 Mn |
| Mar 31, 2022 | 51.00 Mn |
| Dec 31, 2021 | 3.74 Bn |
| Sep 30, 2021 | 12.00 Mn |
| Jun 30, 2021 | 12.00 Mn |
| Mar 31, 2021 | 12.00 Mn |
| Dec 31, 2020 | 476.00 Mn |
| Sep 30, 2020 | 476.00 Mn |